JP2016510315A5 - - Google Patents

Download PDF

Info

Publication number
JP2016510315A5
JP2016510315A5 JP2015548630A JP2015548630A JP2016510315A5 JP 2016510315 A5 JP2016510315 A5 JP 2016510315A5 JP 2015548630 A JP2015548630 A JP 2015548630A JP 2015548630 A JP2015548630 A JP 2015548630A JP 2016510315 A5 JP2016510315 A5 JP 2016510315A5
Authority
JP
Japan
Prior art keywords
combination
combination according
tissue factor
fusion protein
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015548630A
Other languages
English (en)
Other versions
JP6518591B2 (ja
JP2016510315A (ja
Filing date
Publication date
Priority claimed from EP12198839.8A external-priority patent/EP2745852A1/en
Application filed filed Critical
Publication of JP2016510315A publication Critical patent/JP2016510315A/ja
Publication of JP2016510315A5 publication Critical patent/JP2016510315A5/ja
Application granted granted Critical
Publication of JP6518591B2 publication Critical patent/JP6518591B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (15)

  1. 脂質修飾組織因子、トロンビン及びフィブリノーゲンを含む組み合わせ。
  2. 組織因子のN−グリコシル化部位の少なくとも1個が機能していない、請求項1に記載の組み合わせ。
  3. 前記組織因子が、組織因子タンパク質を含む第1の部分と、別のペプチド又はタンパク質を含む第2の部分とを含む融合タンパク質である、請求項1又は2に記載の組み合わせ。
  4. 第2の部分がタグである、請求項3に記載の組み合わせ。
  5. 融合タンパク質が、N−グリコシル化部位の少なくとも1個が機能していない成熟ヒト組織因子タンパク質を含む第1の部分と、His−タグを含む第2の部分とを有する、請求項1から4の何れか一項に記載の組み合わせ。
  6. 融合タンパク質が配列番号5に対応する、請求項5に記載の組み合わせ。
  7. 脂質修飾TFが微小胞中に挿入されている、請求項6に記載の組み合わせ。
  8. トロンビンがヒトトロンビンである、請求項1からの何れか一項に記載の組み合わせ。
  9. フィブリノーゲンがヒトフィブリノーゲンである、請求項1からの何れか一項に記載の組み合わせ。
  10. 請求項1から9の何れか一項に記載の組み合わせと、物質キャリアとを含むシーラント組成物。
  11. 治療上有効な量の、請求項1から9の何れか一項に記載の組み合わせを、その他の適切な薬学的に又は獣医学的に許容される賦形剤及び/又はキャリアと共に含む薬学的組成物。
  12. 請求項1から9の何れか一項に記載の組み合わせ又は請求項10に記載の組成物のシーラント剤としての使用。
  13. 求項1から9の何れか一項に記載の組み合わせ又は請求項10若しくは11に記載の組成物を含む、医薬
  14. 出血の治療ための、請求項1から9の何れか一項に記載の組み合わせ又は請求項10若しくは11に記載の組成物を含む、医薬
  15. 請求項1から9の何れか一項に記載の組み合わせと、組み合わせを構成する全ての成分の同時投与を可能にするアプリケータとを含むキット。
JP2015548630A 2012-12-21 2013-12-20 シーラント組成物 Expired - Fee Related JP6518591B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12198839.8A EP2745852A1 (en) 2012-12-21 2012-12-21 Sealant compositions
EP12198839.8 2012-12-21
PCT/EP2013/077674 WO2014096354A1 (en) 2012-12-21 2013-12-20 Sealant compositions

Publications (3)

Publication Number Publication Date
JP2016510315A JP2016510315A (ja) 2016-04-07
JP2016510315A5 true JP2016510315A5 (ja) 2017-02-09
JP6518591B2 JP6518591B2 (ja) 2019-05-22

Family

ID=47563088

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015548630A Expired - Fee Related JP6518591B2 (ja) 2012-12-21 2013-12-20 シーラント組成物

Country Status (17)

Country Link
US (1) US20160082145A1 (ja)
EP (2) EP2745852A1 (ja)
JP (1) JP6518591B2 (ja)
CN (1) CN104955493A (ja)
AU (1) AU2013366544B2 (ja)
BR (1) BR112015014926B1 (ja)
CY (1) CY1118938T1 (ja)
DK (1) DK2934612T3 (ja)
ES (1) ES2627053T3 (ja)
HR (1) HRP20170880T1 (ja)
HU (1) HUE034649T2 (ja)
LT (1) LT2934612T (ja)
MX (1) MX361222B (ja)
PL (1) PL2934612T3 (ja)
PT (1) PT2934612T (ja)
SI (1) SI2934612T1 (ja)
WO (1) WO2014096354A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109010906B (zh) * 2018-08-16 2021-05-14 陈明远 一种促进术后伤口局部止血及促进术后创面上皮化的生物胶水及其工作方法
US11666682B2 (en) * 2020-08-31 2023-06-06 Ethicon, Inc. Method of stopping CSF leaks and apparatus therefor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022316A1 (en) * 1994-02-17 1995-08-24 New York Blood Center, Inc. Biologic bioadhesive compositions containing fibrin glue and liposomes, methods of preparation and use
JP2002514948A (ja) * 1996-02-20 2002-05-21 コーヒージョン・コーポレーション 組織シーラント組成物とその使用方法
AU9786198A (en) * 1997-10-10 1999-05-03 University Of Virginia Use of fibrin sealant to maintain hemostasis, lymphostasis and prevent local accumulation of body fluids
EP1749536A1 (en) * 2005-08-03 2007-02-07 Thrombotargets Europe, S.L. Activated factor X stimulants as new antihemorrhagic agents for topical use
EP1939218A1 (en) * 2006-12-29 2008-07-02 Thrombotargets Europe, S.L. Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof
EP2145695A1 (de) 2008-07-14 2010-01-20 Sika Technology AG Vorrichtung zur Klebstoffapplikation
EP2380905A1 (en) 2010-04-19 2011-10-26 Thrombotargets Europe, S.L. Phospholipid-enriched vesicles bearing tissue factor having haemostatic activities and uses thereof

Similar Documents

Publication Publication Date Title
WO2017100700A3 (en) Peptides for renal therapy
AR088044A1 (es) Proteinas de fusion para tratar trastornos metabolicos
MX2018005194A (es) Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas.
EP3501546A3 (de) Cystein-wirkstoff konjugate und ihre verwendung
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
WO2010048275A3 (en) Lyophilized recombinant vwf formulations
MX369818B (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
AR077764A1 (es) Polipeptidos selectivos para integrina alfavbeta 3 conjugados a una variante de seroalbumina humana (hsa) y usos farmaceuticos de los mismos
NZ603200A (en) Peptides and their use
WO2014150600A8 (en) Modified toxins
PE20140616A1 (es) Composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecan (folfiri)
WO2014150375A3 (en) Treatment of collagen defects using protein solutions
WO2012006516A3 (en) Protein kinase c activators and anticoagulant for the treatment of stroke
CL2007002689A1 (es) Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
WO2014165607A3 (en) Aromatic-cationic peptide formulations, compositions and methods of use
BR112013000842A2 (pt) composições farmacêuticas, método de tratamento de condição de etiologia funcional do trato gastrointestinal e uso de forma potenciada ativada de anticorpo para a proteína s-100, de forma potenciada ativada de anticorpo para histamina e de forma potenciada ativada de anticorpo para a tnf-alfa.
CL2009001077A1 (es) Vehiculo particulado polimerico que comprende un agente biologico en fase acuosa en un lumen hueco; procedimiento para suministrar una proteina en el ojo; composicion farmaceutica que comprende dicho vehiculo; y su uso para profilaxis y tratar enfermedades o trastornos del ojo.
WO2014153385A3 (en) Methods of treating metabolic disorders
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
MX2016007682A (es) Composicion farmaceutica que comprende ivabradina amorfa.
WO2010132690A3 (en) Compositions and methods for promoting tissue repair and wound healing
WO2011002422A3 (en) Solubility enhancing pharmaceutical formulation
EP4275751A3 (en) Improved naglu fusion protein formulation
WO2014204854A8 (en) Compositions and methods for the preparation of kidney protective agents comprising amifostine and amino acids